ICCT Stock Plummets 99.89% on NASDAQ: iCoreConnect Inc. Faces Severe Decline

ICCT stock has experienced a catastrophic collapse, plummeting 99.89% to just $0.000001 USD on NASDAQ as of April 15, 2026. iCoreConnect Inc., a healthcare software company based in Ocoee, Florida, now trades at penny stock levels with a market capitalization of only $2,439. The company’s ICCT stock price has fallen from a 52-week high of $4.30 to near-zero valuations. This dramatic decline reflects severe operational challenges, negative earnings of -$45.78 per share, and deteriorating financial metrics that have alarmed investors.

ICCT Stock Price Collapse: What Happened

iCoreConnect Inc. (ICCT) has become one of the most severe losers on NASDAQ, with ICCT stock down 99.88% in a single day. The stock traded at just $0.000001, representing a loss of $0.000899 from the previous close of $0.0009. Trading volume reached only 100 shares, well below the average of 1,984 shares, indicating minimal liquidity and investor interest.

The year-to-date decline for ICCT stock stands at -66.67%, while the one-year loss reaches -99.99%. From its 52-week high of $4.30, the stock has lost virtually all value. This represents one of the most severe equity collapses in recent market history, raising serious questions about the company’s viability and future operations.

Financial Metrics Show Deep Distress

ICCT stock’s fundamental metrics paint a bleak picture. The company reported negative earnings per share of -$45.78, making traditional valuation metrics meaningless. The price-to-sales ratio sits at an extremely low 0.00023, reflecting the stock’s penny status. Revenue per share reached $29.42, but this cannot offset massive operating losses.

The current ratio of 0.095 indicates severe liquidity problems, meaning ICCT has only $0.095 in current assets for every dollar of current liabilities. Working capital stands at -$11.25 million, showing the company burns cash faster than it generates it. Free cash flow per share is negative at -$12.69, confirming ongoing cash burn. Track ICCT on Meyka for real-time updates on these deteriorating metrics.

Meyka AI Rating and Market Sentiment

Meyka AI rates ICCT with a grade of B, suggesting a HOLD recommendation despite the stock’s catastrophic decline. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, the company rating shows a C overall with a Sell recommendation, reflecting mixed signals in the market.

The technical picture shows an ADX of 78.20, indicating a strong downtrend. The RSI at 46.62 suggests oversold conditions, while the Stochastic %K at 24.14 confirms extreme weakness. The Williams %R at -75.04 indicates severe selling pressure. These grades are not guaranteed and we are not financial advisors.

Revenue Growth Cannot Offset Operating Losses

Despite revenue growth of 31.83% year-over-year, iCoreConnect Inc. cannot translate top-line expansion into profitability. Gross profit grew 34.75%, but operating income fell 50.90%, revealing severe cost control issues. Net income declined 100.34%, meaning the company went from minimal profits to substantial losses.

The operating profit margin stands at -144.30%, indicating the company loses $1.44 for every dollar of revenue. The net profit margin is equally dire at -289.94%. Return on assets is -5.47%, while return on equity is 11.65%, a contradiction suggesting negative book value. These metrics show ICCT stock faces fundamental business model challenges.

Debt and Liquidity Crisis Deepens

iCoreConnect Inc. faces a severe debt crisis with a debt-to-market cap ratio of 3,629.30, meaning debt exceeds market value by over 36 times. The debt-to-assets ratio of 1.56 indicates liabilities exceed total assets. Interest coverage of -4.75 shows the company cannot service debt from operating earnings.

Cash per share is only $0.55, providing minimal runway for operations. The company has 4.88 million shares outstanding, diluting existing shareholders. With negative operating cash flow of -$8.85 per share and free cash flow of -$12.69 per share, ICCT stock holders face ongoing dilution risks as the company burns through remaining cash reserves.

Healthcare Software Market and Competitive Pressures

iCoreConnect operates in the Medical Healthcare Information Services sector, providing HIPAA-compliant SaaS solutions including electronic prescriptions, insurance verification, and medical coding software. The company competes against well-capitalized competitors with stronger balance sheets and market presence.

With only 67 full-time employees and minimal market traction, ICCT stock reflects the company’s inability to scale operations profitably. The company’s product suite, including iCoreRx, iCoreVerify, and iCoreClaims, addresses real healthcare needs, but execution failures have destroyed shareholder value. The next earnings announcement is scheduled for May 28, 2026, which may provide clarity on turnaround prospects.

Final Thoughts

ICCT stock represents one of the most severe equity collapses on NASDAQ, with iCoreConnect Inc. trading at penny stock levels after a 99.89% decline. The company faces multiple existential challenges: negative earnings of -$45.78 per share, severe liquidity constraints with a current ratio of 0.095, and massive cash burn of -$12.69 per share in free cash flow. Revenue growth of 31.83% cannot offset operating losses, with the company losing $1.44 for every dollar of sales. The debt-to-market cap ratio of 3,629.30 indicates insolvency concerns. While Meyka AI assigns a B grade with a HOLD recommendation, the company’s fundamental metrics suggest extreme distress. Investors should exercise extreme caution, as ICCT stock faces potential delisting or restructuring. The May 28 earnings report may provide critical information about survival prospects. These grades are not guaranteed and we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.